|
Canada-0-Pubs कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Stivarga: Uses, Dosage, Side Effects Warnings - Drugs. com
Stivarga (regorafenib) is used to treat metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma Includes Stivarga side effects, interactions and indications -Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy,
- What is STIVARGA ® (regorafenib)? - Stivarga US Patient Oct13
STIVARGA is a once-daily, prescription anticancer medicine for patients who have received previous treatment with certain chemotherapy medicines to treat colon cancer (CRC) that has now spread to other parts of the body
- Stivarga - Chemocare
This is not uncommon as chemotherapy can affect healthy cells as well as cancer cells Report any side effects Continue your course of treatment even though you feel ill unless your care team tells you to stop Before having surgery, talk to your care team to make sure it is ok This medication can increase the risk of poor healing of your
- Stivarga: Cancer Treatment Uses, Side Effects Dosage - MedicineNet
Stivarga is a chemotherapy drug used to treat colon or rectal cancer that has spread to other parts of the body, a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumors), and a type of liver cancer called hepatocellular carcinoma (HCC) Chemotherapy is an aggressive cancer treatment that uses powerful drugs
- STIVARGA® (regorafenib) | Official HCP Website
Indications STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy STIVARGA is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal
- Regorafenib - Wikipedia
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK) Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition Since 2009 it was studied as a potential treatment option in multiple tumor types [2]
- Frequently Asked Questions About Stivarga® - CancerConnect
Stivarga is used to treat patients with metastatic colorectal cancer that has previously been treated with certain types of chemotherapy and other medications Stivarga is also used for a rare cancer called a GIST (gastrointestinal stomach tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which
- Regorafenib (Stivarga) | Cancer information - Cancer Research UK
Regorafenib Regorafenib is a targeted cancer drug You pronounce regorafenib as re-gor-af-e-nib It is also known as Stivarga You might have it as a treatment for: gastro intestinal stromal cancer (GIST) – a rare type of soft tissue sarcoma of the stomach or intestines
- Stivarga (Regorafenib Tablets): Side Effects, Uses, Dosage . . . - RxList
Stivarga (Regorafenib Tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources Eleven patients received irinotecan-containing combination chemotherapy with STIVARGA at a dose of 160 mg The mean AUC of irinotecan increased by 28%
- DailyMed - STIVARGA- regorafenib tablet, film coated
STIVARGA is a kinase inhibitor indicated for the treatment of patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy 1 1
|
|